Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SecuraBio
Phase IV, multicenter, prospective observational study in a real world (RW) setting, designed to observe the utilization and effectiveness of PI3K-inhibitor treatment, and HRQoL of patients with CLL/SLL/FL outside the context of a clinical trial.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical or pathological diagnosis of CLL/SLL according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) diagnosis guideline or pathological diagnosis of FL, for whom the Investigator has decided that PI3K-inhibitor treatment is the appropriate therapy
* Patients previously treated with PI3K-inhibitors are eligible for this study if they:
* Are restarting treatment with PI3K-inhibitor at enrollment, or
* Restarted PI3K-inhibitor treatment within 3 treatment cycles prior to enrollment
* Patients newly treated with PI3K-inhibitors are eligible for this study if they:
* Are starting treatment with PI3K-inhibitors at enrollment, or
* Started on PI3K-inhibitor treatment within 3 treatment cycles prior to enrollment
≥18 years of age at time consent is provided to participate in this study
For patients treated with PI3K-inhibitors prior to enrollment in the study, availability of documentation of previous PI3K-inhibitor treatment, including the start date of previous or current PI3K-inhibitor treatment in patient charts or medical records
Patient is willing and able to provide a signed and dated Institutional Review Board (IRB)-approved informed consent form (ICF)
You may not be if
Not applicable
Clareo Health | Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
